Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Montreal Heart Institute | OTHER |
| Somahlution LLC | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a 9-months extension to the following study, protocol number: 003-03: "A study to evaluate the use of SOMVC001 (GALA) vascular conduit preservation solution in patients undergoing coronary artery bypass grafting (GABG)". Participation is allowed exclusively to participants enrolled in the main protocol SOMVC001 (GALA).
Patients enrolled in this 9-months extension study of SOMVC001 (GALA) will be contacted by phone twice: 6 months and 9 months after a coronary artery bypass graft (CABG) surgery. During these phone call visits and at twelve months post CABG surgery, adverse events and/or concomitant medication changes will be collected from the participant. Twelve months after the CABG surgery procedure, imaging will be performed using 64-slice or better MDCT-scan angiography. The study participation ends at this MDCT-scan visit.
In detail, will be recorded incidence of composite safety outcomes consisting of Major Adverse Cardiac Events (MACE) (death, myocardial infarction [MI], and repeat revascularization), angina, arrhythmias, shortness of breath [SOB], decreased lumen change, graft occlusion and significant stenosis based on Fitzgibbon's scale B and O, following CABG surgery.
Patients in this study are their own control; they receive two SVG; one exposed to GALA and the other exposed to heparinized dose saline. The effect of treatment (GALA vs. Saline) will be evaluated on paired grafts within-person. Therefore, treatment effect will be presented by graft and not by patient. Only adverse clinical events will be presented by patient including their potential relationship to the study product.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| CABG patients from protocol 003-03 | Patients who will agree to be followed for an additional 9 months, which include: 2 phone calls at 6 and 9 months after coronary artery bypass graft surgery 1 clinic visit at 12 months after coronary artery bypass graft surgery ( 64-slice or better MDCT angiography) |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| It will be measured and reported, the mean lumen diameter of paired grafts (one treated vs one not treated) within-person. Mean lumen diameter will be expressed in millimeter (mm) . | performing a 64-slice or better multi-detector computed tomography (MDCT) angiography, by assessing the magnitude of change in the mean lumen diameter of paired grafts within person, one year post- surgery. | At twelve months following CABG surgery |
| It will be measured and reported, the maximum stenosis of paired grafts (one treated vs one not treated) within-person. The maximum stenosis will be expressed in millimeter (mm). | Performing a 64-slice or better multi-detector computed tomography (MDCT) angiography by assessing the magnitude of change at maximum stenosis of paired grafts within person, one year post-surgery. | At twelve months following CABG surgery |
| The incidence of vein graft thrombosis will be measured as total graft occlusion | Using a 64-slice or better multi-detector computed tomography (MDCT) angiography. | At twelve months following CABG surgery |
| Measure | Description | Time Frame |
|---|---|---|
| The change in maximal stenosis will be measured and expressed in millimeter (mm) as changes over time. | Using a 64-slice or better multi-detector computed tomography (MDCT) angiography. | from 4-6 weeks to 12 months and from 3 months to 12 months following CABG surgery |
| The change in lumen will be measured and expressed in millimeter (mm) as changes over time. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients who had a coronary artery bypass graft surgery (CABG), and took part in previous main study of SOMVC001 (GALA) protocol ID # 003-03 .
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Louis P Perrault, MD, PhD | Montreal Heart Institute | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Montreal Heart Institute | Montreal | Quebec | J0N 1P0 | Canada |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 29682294 | Derived | Ben Ali W, Voisine P, Olsen PS, Jeanmart H, Noiseux N, Goeken T, Satishchandran V, Cademartiri F, Cutter G, Veerasingam D, Brown C, Emmert MY, Perrault LP. DuraGraft vascular conduit preservation solution in patients undergoing coronary artery bypass grafting: rationale and design of a within-patient randomised multicentre trial. Open Heart. 2018 Apr 13;5(1):e000780. doi: 10.1136/openhrt-2018-000780. eCollection 2018. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003324 | Coronary Artery Disease |
| ID | Term |
|---|---|
| D003327 | Coronary Disease |
| D017202 | Myocardial Ischemia |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Using a 64-slice or better multi-detector computed tomography (MDCT) angiography. |
| from 4-6 weeks to 12 months and from 3 months to 12 months following CABG surgery. |
| The change in vessel diameter will be measured and expressed in millimeter (mm) as changes over time. | Using a 64-slice or better multi-detector computed tomography (MDCT) angiography. | from 4-6 weeks to 12 months and from 3 months to 12 months following CABG surgery |
| The change in total wall thickness will be measured and expressed in millimeter (mm) as changes over time. | Using a 64-slice or better multi-detector computed tomography (MDCT) angiography. | from 4-6 weeks to 12 months and from 3 months to 12 months following CABG surgery |
| D001161 |
| Arteriosclerosis |
| D001157 | Arterial Occlusive Diseases |
| D014652 | Vascular Diseases |